| dc.description.abstract | Background: Eye tumors have a high level of severity and can threaten vision and life. The
antioxidant glutathione peroxidase is produced by the body to reduce damage caused by
free radicals. Therefore, glutathione peroxidase can be used as a potential biomarker to
evaluate the level of oxidative stress and antioxidant status in eye tumor patients.
Objective: To determine the relationship between serum glutathione peroxidase levels and
the incidence of eye tumors.
Materials and Methods: This study used a case-control design as an observational analytic
approach. In this study, there were 21 subjects with eye tumors in the study group, and 21
subjects without eye tumors in the control group. Sampling was carried out from August
2022 to December 2022 at the Ophthalmic Clinic of the Reconstructive, Ocuplasty, and
Oncology division.
Results: The study group had 21 subjects with eye tumors, with the largest group being
female subjects, totaling 12 individuals (57.1%). Most subjects in this age group were
between 41-50 years old and worked indoors (61.9%). The most common type of malignant
tumor in this group was basal cell carcinoma with a percentage of 30%, while the most
common types of benign tumors were epidermoid cysts and conjunctival cysts, both with
the same percentage of 36.4%. There was a significant relationship between serum
glutathione peroxidase levels and patients with eye tumors (p<0.001), with a mean serum
glutathione peroxidase level in the group of subjects with eye tumors of 61.68 U/mL.
However, there was no significant difference in serum glutathione peroxidase levels
between subjects with malignant eye tumors and subjects with benign eye tumors.
Conclusion: In the case group, there was a significant relationship between serum
glutathione peroxidase levels and eye tumors (p <0.001). | en_US |
